Clinical Trials Directory

Patients with diabetic macular edema who were switched to aflibercept after having been treated with bevacizumab or ranibizumab were retrospectively reviewed to assess for visual acuity and anatomic outcomes.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : Intravitreal Injection of Aflibercept

Phase: N/A


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

Those patients with diabetic macular edema switched to aflibercept from bevacizumab and/or ranibizumab -

External Links

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Theodore Leng, MD
Not Recruiting

Footer Links: